416 reports of this reaction
1.5% of all BICALUTAMIDE reports
#16 most reported adverse reaction
METASTASES TO BONE is the #16 most commonly reported adverse reaction for BICALUTAMIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 416 FDA adverse event reports linking BICALUTAMIDE to METASTASES TO BONE. This represents approximately 1.5% of all 27,404 adverse event reports for this drug.
Patients taking BICALUTAMIDE who experience metastases to bone should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
METASTASES TO BONE is a less commonly reported adverse event for BICALUTAMIDE, but still significant enough to appear in the safety profile.
In addition to metastases to bone, the following adverse reactions have been reported for BICALUTAMIDE:
The following drugs have also been linked to metastases to bone in FDA adverse event reports:
METASTASES TO BONE has been reported as an adverse event in 416 FDA reports for BICALUTAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
METASTASES TO BONE accounts for approximately 1.5% of all adverse event reports for BICALUTAMIDE, making it a notable side effect.
If you experience metastases to bone while taking BICALUTAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.